References
- Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 10, 428–438 (2011).
- Scannell JW, Blanckley A, Boldon AH, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191–200 (2012).
- Halim AB. Biomarkers in drug development: a useful tool but discrepant results may have a major impact. In: Drug Discovery and Development – Present and Future. Kapetanovic IM ( Ed.). InTech Publishers, Croatia, 401–424 (2011).
- Chapman PB, Hauschild A, Robert AC et al. Improved survival with Vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
- Malone B. Big changes coming to molecular DX reimbursement. Clin. Lab. News 37(9), 1 (2011).
- Malone B. Molecular diagnostics reimbursement in flux. Clin. Lab. News 39(1), 1 (2013).
- Stanek EJ, Sanders CL, Johansen-Taber KA et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91(3), 450–458 (2012).
- Voight BF, Peloso GM, Orho-Melander M et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380, 572–580 (2012).
- Harrison SC, Holmes MV, Humphries SE. Mendelian randomisation, lipids, and cardiovascular disease. Lancet 380, 543–545 (2012).
- Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).
- Bedard PL, Hansen AR, Ratain MJ and Siu LL. Tumour heterogeneity in the clinic. Nature 501, 355–364 (2013).
- Bonini P, Plebani M, Ceriotti F and Rubboli F. Errors in laboratory medicine. Clin. Chem. 48(5), 691–698 (2002).
- Halim AB. Impact of discrepant results from clinical laboratories on patients and pharmaceutical trials: evidence from proficiency testing results. Biomarkers Med. 3, 231–238 (2009).
- Halim AB. Discrepant results from laboratories impact patients receiving heparin or antithrombin therapy. Biomarkers Med. 5, 211–218 (2011).
- Halim AB. Proficiency testing for monitoring global laboratory performance and identifying discordance. Lab. Med. 44, e19–e30 (2013).
- Press MF, Hung G, Godolphin W and Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 54, 2771–2777 (1994).
- Thomson TA, Hayes MM, Spinelli JJ et al. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod. Pathol. 14, 1079–1086 (2001).
- Wolff AC, Elizabeth M, Hammond H et al. American society of clinical oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 131, 18–43 (2007).
- Hammond MEH, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28, 2784–2795 (2010).
- Malone, B. The Pursuit of Traceability. Clin. Lab. News 35(10), 1 (2009).
- Robarge J D, Li L, Desta Z, Nguyen A, Flockhart DA. The star-allele nomenclature: retooling for translational genomics. Clin. Pharm. Ther. 82, 244–248 (2007).
Websites
- US FDA table of pharmacogenomic biomarkers in drug labels. www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm ( Accessed 20 May 2013)
- Naylor S, Cole T. Overview of companion diagnostics in the pharmaceutical industry. Drug Discovery World (Spring), 67–79 (2010). www.ddw-online.com/personalised-medicine/p92845-overview%20of%20companion%20diagnostics%20in%20the%20pharmaceutical%20industry.%20%20spring%2010.html ( Accessed 20 May 2013)
- Reuters: UPDATE 3-US FDA approves Roche skin cancer drug Zelboraf. www.reuters.com/article/2011/08/17/roche-zelboraf-idUSN1E77G0BW20110817 ( Accessed 20 May 2013)
- Diagnostics 2011: M&A surges, companion diagnostics accelerate, and early detection offers new prospects. www.pwc.com/diagnostics2011 ( Accessed 20 May 2013)
- US FDA companion diagnostic devices: in vitro and imaging tools. www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm ( Accessed 20 May 2013)
- Michel RL. Low 2013 molecular rates may bankrupt some labs. The Dark Report, 11th February (2013). www.darkreport.com ( Accessed 25 September 2013)
- Medscape: Molecular testing has a long way to go. National Comprehensive Cancer Network (NCCN) 16th Annual Conference, 12 March 2011. www.medscape.com/viewarticle/739507 ( Accessed 20 May 2013)
- FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer. Roche (Media Release), 11th June (2012). www.roche.com/media/media_releases/med-cor-2012-06-11.htm ( Accessed 20 May 2013)
- HercepTest™, kit insert. Dako, Denmark. www.dako.com/28633_04may10_herceptest__brochure-9086.pdf ( Accessed 20 May 2013)
- FDA guidance for industry and food and drug administration staff - in vitro companion diagnostic devices, July 2011. www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm262292.htm ( Accessed 2 August 2011)